SCHEMBL25372676

SCHEMBL25372676

COc1ccc(Nc2nccc3c(NC(=O)c4cnc5c(N)ncnn45)c(C)ccc23)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 8/20 0.51
▸ BRAF P15056 8/20 0.51
▸ CSF1R P07333 5/20 0.51
▸ DDR1 Q08345 5/20 0.51
▸ DDR2 Q16832 5/20 0.51
▸ PIP4K2A P48426 9/20 0.44
▸ MAPT P10636 4/20 0.43
▸ ARAF P10398 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29638554 1.00 RAF1 (0.51) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL24399605 0.89 RAF1 (0.63) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL29638514 0.89 RAF1 (0.63) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL29638605 0.86 RAF1 (0.62) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL24399635 0.86 RAF1 (0.62) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL24399601 0.81 BRAF (0.49) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL29638591 0.81 BRAF (0.49) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL24399631 0.81 RAF1 (0.64) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL24399761 0.81 BRAF (0.56) RAF1BRAFCSF1RDDR1DDR2
SCHEMBL29638586 0.81 BRAF (0.56) RAF1BRAFCSF1RDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM RAF1 2075/4885BRAF 720/4885CSF1R 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback